‘NRG-GY001: A Phase II Trial of Cabozantinib (XL-184) (NSC #761968) in Women with Recurrent, Clear Cell Carcinoma of the Ovary, Fallopian Tube, or Peritoneum’ of page ‘NRG-GY001’
Principal Investigator/Co-Principal Investigator John H Farley, MD/Panagiotis Konstantinopoulos, MD, PhD Primary Objective To evaluate the anti-tumor activity of cabozantinib (XL184) in women with persistent or recurrent clear cell ovarian cancer, based on the proportion of patients who survive progression-free for at least 6 months and the proportion who have objective tumor response (complete or partial). […]
Read More